Navigation Links
Azixa in Medical News

EpiCept Corporation Announces Pricing of Public Offering

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...tions, unknown risks or uncertainties or other risk factors. EPCT-GEN * azixa is a registered trademark of Myriad Genetics, Inc. ...

EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology

...e regulatory approval or achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...tions, unknown risks or uncertainties or other risk factors. EPCT-GEN * azixa is a registered trademark of Myriad Genetics, Inc. ...

EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that EpiCept will not receive any significant payments under ...

EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results

... had initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...d to the brain. Two additional Phase II trials for azixa are also underway in Glioblastoma multiforme and i...of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve si...

EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007

...e, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...urate assumptions, unknown risks or uncertainties or other risk factors. * azixa is a registered trademark of Myriad Genetics, Inc. EPCT-GEN ...

EpiCept Corporation to Present at the 2007 BIO InvestorForum

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Accelerates Development of Phase I Clinical Study for Cancer

...n metastases due to melanoma. EpiCept's licensing agreement with Myriad for azixa includes milestone payments, and sublicensing income as well as future royalties in the event Myriad's development of azixa continues to progress successfully.
Azixa in Medical Technology

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCept Corporation today announced the results of scientific studies that (1) demonstrate that Azixa(TM) (MPC-6827) is effective in treating multiple types of human tumors in animal models, (2) rev...

EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Regulatory Progress on Ceplene(TM)

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... has initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...these patients. Two additional Phase II trials for azixa are underway in primary brain cancer and melanoma ...f Executive Officer. "We believe that the study of azixa in this new indication affords EpiCept with an exp...

Myriad Genetics Presents Azixa's Mode of Action at AACR

... azixa Shows Dual Activity as Vascular Disrupting Agent a...ncer Research (AACR) in Los Angeles, California. azixa has been previously shown to be an inducer of apop...nd subsequent tumor cell death. In recent studies, azixa induced cell death in several primary types of end...

Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

...ubsequent tumor cell death. Myriad reported that azixa induced cell death in several primary types of a t... human ovarian cancer xenografts, a single dose of azixa induced dramatic tumor blood vessel damage and tum...ation of the substantial clinical opportunity that azixa represents," remarked Jack Talley, President and C...

EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting

...y cause actual results or developments to differ materially include: the risk that Myriad's development of Azixa will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...
Azixa in Biological Technology

EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference

...plene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... has initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...these patients. Two additional Phase II trials for azixa are underway in primary brain cancer and melanoma ...f Executive Officer. "We believe that the study of azixa in this new indication affords EpiCept with an exp...
Other Tags
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... novel compound that targets an important brain receptor has ... behaviors, including relapse behavior, a University at Buffalo animal ... that this may be a novel lead compound for ... The UB research was published as an online preview ... the study, the compound, RO5263397, severely blunted a broad ...
(Date:4/23/2014)... accessible detection methods that can rapidly screen a ... single cell inside that population has been seriously ... , In the Royal Society of Chemistry journal ... he and his coworkers have developed a novel ... protein ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
(Date:4/23/2014)... of asthma, allergies and other chronic inflammatory disorders among ... part to their reduced exposure to the microbes that ... paper. , The article, published in the journal ... in urban centers who have less access to green ... a condition caused by immune system dysfunction. , When ...
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... People who have had a stroke, often suffer motor ... a study conducted in Taiwan, that will be published ... but is currently freely available on-line as an unedited ... when one group of stroke victims had their own ... brain and a similar group did not, those who ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
Other Contents